Mahnaz Shariatzadeh1, Maarten M Brandt2, Caroline Cheng2,3, Josianne C Ten Berge4, Aniki Rothova4, Pieter J M Leenen5, Willem A Dik6. 1. Department of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands. m.shariatzadeh@erasmusmc.nl. 2. Division of Experimental Cardiology, Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands. 3. Department of Nephrology and Hypertension, DIGD, University Medical Center Utrecht, Utrecht, The Netherlands. 4. Department of Ophthalmology, Erasmus University Medical Center, Rotterdam, The Netherlands. 5. Department of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands. 6. Department of Immunology, Laboratory Medical Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Abstract
PURPOSE: This study is aimed to adapt a three-dimensional (3-D) in vitro angiogenesis model to the ophthalmology field using retinal endothelial cells (REC). This system is applied to assess the angiogenic capacity of aqueous humor (AH) from patients with ocular disorders, and to test the effect of VEGF inhibitor (aflibercept) on induced angiogenesis. METHODS: Human REC and umbilical vein endothelial cells (HUVEC) and pericytes were co-cultured in a gel matrix with 25-200 ng/ml pro-angiogenic growth factors (GF). AH from patients with cataract, glaucoma or proliferative diabetic retinopathy (PDR) was tested in the REC-pericyte co-culture. Aflibercept was then introduced to the co-culture containing PDR AH. The surface area and total tubule length were measured using Image J. RESULTS: Optimal GF concentrations at 200 ng/ml induced angiogenesis by REC as well as HUVEC, while vessel formation by both cell types was strongly reduced using 25-50 ng/ml GF. Addition of AH from the PDR patient triggered tubule formation by REC at low GF concentration. Aflibercept, however, significantly inhibited angiogenesis induced by PDR AH, but showed no significant influence on other conditions. CONCLUSION: REC can be applied efficiently in the 3-D in vitro angiogenesis model as a diagnostic tool to assess the AH angiogenic status and to validate new anti-angiogenic therapeutic compounds prior to clinical trial.
PURPOSE: This study is aimed to adapt a three-dimensional (3-D) in vitro angiogenesis model to the ophthalmology field using retinal endothelial cells (REC). This system is applied to assess the angiogenic capacity of aqueous humor (AH) from patients with ocular disorders, and to test the effect of VEGF inhibitor (aflibercept) on induced angiogenesis. METHODS:Human REC and umbilical vein endothelial cells (HUVEC) and pericytes were co-cultured in a gel matrix with 25-200 ng/ml pro-angiogenic growth factors (GF). AH from patients with cataract, glaucoma or proliferative diabetic retinopathy (PDR) was tested in the REC-pericyte co-culture. Aflibercept was then introduced to the co-culture containing PDR AH. The surface area and total tubule length were measured using Image J. RESULTS: Optimal GF concentrations at 200 ng/ml induced angiogenesis by REC as well as HUVEC, while vessel formation by both cell types was strongly reduced using 25-50 ng/ml GF. Addition of AH from the PDR patient triggered tubule formation by REC at low GF concentration. Aflibercept, however, significantly inhibited angiogenesis induced by PDR AH, but showed no significant influence on other conditions. CONCLUSION: REC can be applied efficiently in the 3-D in vitro angiogenesis model as a diagnostic tool to assess the AH angiogenic status and to validate new anti-angiogenic therapeutic compounds prior to clinical trial.
Authors: Ihsan Chrifi; Laura Louzao-Martinez; Maarten Brandt; Christian G M van Dijk; Petra Burgisser; Changbin Zhu; Johan M Kros; Dirk J Duncker; Caroline Cheng Journal: Arterioscler Thromb Vasc Biol Date: 2017-04-20 Impact factor: 8.311
Authors: Judy R van Beijnum; Patrycja Nowak-Sliwinska; Elisabeth J M Huijbers; Victor L Thijssen; Arjan W Griffioen Journal: Pharmacol Rev Date: 2015 Impact factor: 25.468
Authors: Arpita S Bharadwaj; Binoy Appukuttan; Phillip A Wilmarth; Yuzhen Pan; Andrew J Stempel; Timothy J Chipps; Eric E Benedetti; David O Zamora; Dongseok Choi; Larry L David; Justine R Smith Journal: Prog Retin Eye Res Date: 2012-09-11 Impact factor: 21.198
Authors: C Zhu; I Chrifi; D Mustafa; M van der Weiden; P J M Leenen; D J Duncker; J M Kros; C Cheng Journal: Oncogene Date: 2017-05-22 Impact factor: 9.867